177 search results
- Current search:
- Metabolic and Endocrine Disorders
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
TitlePublished 9 Jul 2017
Hormone replacement therapy for postmenopausal women with type 2 diabetes mellitus
Metabolic and Endocrine Disorders Group Sachiko Kataoka Title Wednesday, July 5, 2017 ... -
TitlePublished 23 Jul 2017
Family based interventions for type 2 diabetes mellitus
Metabolic and Endocrine Disorders Group Khadija Matrook Title Thursday, July 6, 2017 ... -
NewCochrane EvidencePublished 22 Jun 2017
Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years
Review question How effective are diet, physical activity and behavioural interventions in reducing the weight of overweight or obese children aged 6 to 11 years? Background Across the world more children are becoming overweight and obese. These children are more likely to suffer from health problems, both while as children and in later life. More ... -
NewCochrane EvidencePublished 22 Jun 2017
Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years
Review question How effective are diet, physical activity and behavioural interventions in reducing the weight of overweight or obese adolescents aged 12 to 17 years? Background Across the world, more adolescents are becoming overweight and obese. These adolescents are more likely to suffer from health problems in later life. More information is ... -
Cochrane EvidencePublished 12 May 2017
Intermediate hyperglycaemia as a predictor for the development of type 2 diabetes: prognostic factor exemplar review
Protocol: To assess whether intermediate hyperglycaemia is a predictor for the development of type 2 diabetes mellitus (T2DM). -
Cochrane EvidencePublished 10 May 2017
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus
Review question Are the glucose-lowering medicines, DPP-4 inhibitors (e.g. linagliptin or vildagliptin) and GLP-1 analogues (e.g. exenatide or liraglutide) able to prevent or delay the development of type 2 diabetes and its associated complications in people at risk for the development of type 2 diabetes? Background DPP-4 inhibitors and GLP-1 analogues ... -
Cochrane EvidencePublished 8 Mar 2017
Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children
Protocol: To assess the effects of vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children. -
TitlePublished 12 Mar 2017
Interventions for prevention or delay of type 2 diabetes mellitus in women with previous gestational diabetes
Metabolic and Endocrine Disorders Group Joule Li Title Thursday, March 2, 2017 ... -
TitlePublished 12 Feb 2017
Testosterone replacement for treating men with sexual dysfunction
Metabolic and Endocrine Disorders Group Jae Hung Jung Title Thursday, February 9, 2017 ... -
Cochrane EvidencePublished 20 Jan 2017
Open minimally invasive versus video-assisted minimally invasive parathyroidectomy for primary hyperparathyroidism
Protocol: To assess the effects of open minimally invasive versus video-assisted minimally invasive parathyroidectomy for primary hyperparathyroidism.